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Background {#sec004}
==========

Preeclampsia (PE), defined as new-onset hypertension after 20 weeks gestation often with significant proteinuria \[[@pone.0116296.ref001], [@pone.0116296.ref002]\] affects between 2.5% and 7.6% of pregnancies in the general population Worldwide \[[@pone.0116296.ref003]\]. PE is associated with increased maternal and perinatal morbidity and mortality \[[@pone.0116296.ref004]\], cited as the leading cause of admission to the intensive care unit during the puerperal period \[[@pone.0116296.ref005], [@pone.0116296.ref006]\], and is the fourth leading cause of maternal death \[[@pone.0116296.ref007]\]. Additionally, women with PE have a higher risk of placental abruption, and their fetuses have a higher risk of stillbirth, preterm delivery, and intrauterine growth restriction \[[@pone.0116296.ref008]--[@pone.0116296.ref010]\].

Acetylsalicylic acid (ASA) effectively reduces the risk of PE and its aforementioned sequelae \[[@pone.0116296.ref011]--[@pone.0116296.ref014]\], without producing adverse effects on the mother or fetus \[[@pone.0116296.ref003], [@pone.0116296.ref015]\]. Meta-analyses of randomized controlled trials (RCTs) demonstrate a 17% relative risk reduction (RRR) for PE with ASA over placebo \[[@pone.0116296.ref011]\]. ASA prophylaxis started early in the pregnancy, at 12--16 weeks, confers a 53% RRR for PE and a 91% RRR for severe PE \[[@pone.0116296.ref012]--[@pone.0116296.ref014]\]. Important benefits are also seen for the fetus, such as a reduced risk of preterm birth, intrauterine growth restriction and neonatal death and morbidity \[[@pone.0116296.ref012]--[@pone.0116296.ref014]\] ([S1 Table](#pone.0116296.s001){ref-type="supplementary-material"}).

Current guidelines for obstetricians and midwives endorse using ASA for the prevention of PE in women at risk of this condition \[[@pone.0116296.ref001]\]. However, guidance about what level of PE risk warrants ASA prophylaxis is lacking. This uncertainty has resulted in inconsistencies in recommendations and possible underuse of ASA \[[@pone.0116296.ref016]\]. Without an agreed upon threshold of risk for PE, based upon valid algorithms, it is problematic for clinicians to identify which women should receive ASA.

Establishing a threshold level of risk for PE is needed by clinicians, since there is a growing body of evidence that details how different clinical risk factors can forecast PE risk. Based on this evidence, estimates of PE risk range from less than 4% for women with no risk factors up to around 25% for women with just one risk factor, such as chronic hypertension \[[@pone.0116296.ref017], [@pone.0116296.ref018]\]. Other clinical risk factors also heighten the risk. For example, the risk of developing PE is 10% in obese women with a body mass index of 30 kg/m^2^ or greater, increasing to 16% if her systolic blood pressure is also over 120 mm Hg \[[@pone.0116296.ref018]\].

We present two approaches for objectively determining the minimum risk for PE at which ASA prophylaxis is justified. The first is a new approach---the *minimum control event rate* (*CER* ~*min*~). The second approach uses a pre-existing concept---the *minimum event rate for treatment (MERT)* \[[@pone.0116296.ref019]\]. Here we show how the CER~min~ is derived, and then use the CER~min~ and the MERT to guide us to a reasonable risk threshold for starting a woman on ASA prophylaxis against PE based on clinical risk assessment.

Methods and Results {#sec005}
===================

Threshold Number Needed to Treat (NNT~T~) {#sec006}
-----------------------------------------

A useful measure of ASA efficacy in this context is the *number needed to treat* (*NNT*)---the number of patients a clinician needs to treat in order to prevent one target outcome, such as a stroke \[[@pone.0116296.ref019]\]. The *NNT* has been widely adopted to communicate treatment effect sizes in a clinically meaningful way \[[@pone.0116296.ref020]\]. In 2001, Sinclair et al. introduced the idea of using a threshold for the *NNT*---the *NNT* ~*T*~---which is the maximum number of patients a clinician would be willing to treat to prevent one target outcome \[21\]. The *NNT* ~*T*,~ which aims to guide treatment recommendations, is determined by estimating the clinical value of preventing one target event and identifying the number of patients that would need to be treated such that this benefit is equivalent to the negative consequences of treating the same number of patients---both in terms of adverse events and costs \[21\]. In the specific case of using ASA to prevent PE and related outcomes, we herein use the *number needed to prevent* (*NNP*) and the threshold *NNP* ~*T*~.

The value of preventing one target event can be estimated in quality adjusted life years (QALY) gained. To solve for the *NNP* ~*T*~, we assign a \$50 000 value per QALY gained, in accordance with the conventional willingness to pay threshold accepted in cost-effectiveness analysis research \[[@pone.0116296.ref022], [@pone.0116296.ref023]\].

Deriving the Minimum Control Event Rate (CER~min~) {#sec007}
--------------------------------------------------

The CER~min~ is the minimum disease event rate in the placebo control group(s) of one or more RCTs in which the intervention (e.g., ASA) is cost-effective.

To derive the CER~min~ for ASA prophylaxis, we consider both the NNP~T~ and the known prevalence of PE in the ASA treatment groups within the RCTs---the *treatment event rate* (*TER*).

First, we isolate the CER, in terms of TER and NNP: $$\begin{array}{l}
{ARR = CER - TER,~\text{where\ ARR\ is\ the\ absolute\ risk\ reduction}.} \\
{\text{Also},ARR = 1/NNP} \\
{\text{and}~1/NNP = CER - TER} \\
{\text{such\ that}~CER = TER + 1/NNP} \\
\end{array}$$ In the case of CER~min~, we focus on the NNP~T~, which was derived using the equation by Shimbo et al. \[[@pone.0116296.ref024]\], a simplification of that by Sinclair et al. \[[@pone.0116296.ref021]\]: $$NNP_{T} = QALYsgained \times \$ 50\ 000/DC$$ where DC is the direct cost of the treatment for one patient, and QALYs gained is the number of quality adjusted life years gained by avoiding one target event.

Now, substituting the equation for NNP~T~ provided by Shimbo et al. \[[@pone.0116296.ref024]\] into [Equation 1](#pone.0116296.e001){ref-type="disp-formula"}, we can approximate the CER~min~ as follows: $$\begin{array}{l}
{CER_{min} = TER + 1/\left\lbrack {\left( {QALYsgained \times \$ 50\ 000} \right)/DC} \right\rbrack} \\
{= TER + \left\lbrack {DC/\left( {QALYsgained \times \$ 50\ 000} \right)} \right\rbrack} \\
\end{array}$$

Hence, we arrive at the final equation: $$CER_{min} = TER + \left\lbrack {DC/\left( {QALYsgained \times \$ 50\ 000} \right)} \right\rbrack$$

Application of the CER~min~ to preeclampsia prophylaxis with ASA {#sec008}
----------------------------------------------------------------

Using [Equation 2](#pone.0116296.e002){ref-type="disp-formula"} for the CER~min~ we fill in the known values for ASA prophylaxis, namely, the DC, QALYs gained, and TER.

The DC of taking 81 mg baby ASA daily for one year varies between \$14 to \$24 \[[@pone.0116296.ref025], [@pone.0116296.ref026]\], and ASA can be purchased at any drug store. Assuming that a woman needs to take ASA prophylaxis from 12 to 38 weeks gestation, she will pay a DC of \$10.

Next, we consider QALYs gained per case of preeclampsia prevented. In the case of ASA prophylaxis, one analysis considered the benefits to both the mother [and]{.ul} baby, arriving at a value of 0.52 QALYs gained per pregnancy \[[@pone.0116296.ref001]\]. Nonetheless, a value of 0.52 QALYs gained per pregnancy may be a generous estimate, so we determined NNP~T~ values at various QALYs gained, starting at as low as 0.005 QALYs gained ([Fig. 1](#pone.0116296.g001){ref-type="fig"}).

![Threshold number needed to prevent (NNP~T~) at varying quality-adjusted life years (QALYs) gained per preeclampsia event avoided.\
NNP~T~ calculated as: (QALYs gained x \$50000) / DC \[[@pone.0116296.ref024]\], assuming a direct cost (DC) of ASA of \$10 per pregnancy. The dashed blue lines show that, at 0.52 QALYs gained by ASA prophylaxis \[[@pone.0116296.ref001]\], a clinician would be willing to give ASA prophylaxis to as many as 2600 women---the NNP~T~. For a more modest amount of 0.05 QALYs gained, the NNP~T~ would be 250 (dashed red lines). The NNP~T~ is presented on a log~2~ scale for ease of viewing.](pone.0116296.g001){#pone.0116296.g001}

In calculating the CER~min~ by [Equation 2](#pone.0116296.e002){ref-type="disp-formula"}, we first fix the value for QALYs gained at 0.05 and 0.52, and observe how the CER~min~ changes with increasing TER ([Fig. 2](#pone.0116296.g002){ref-type="fig"}). We see that at a DC of \$10, the TER very closely approximates the CER~min~ when QALYs gained is 0.52. At a QALY gain of 0.05, the CER~min~ is 0.4% higher than the TER.

![Minimum control event rate (CER~min~) for preeclampsia with varying treatment event rates (TER) for preeclampsia, at fixed values of 0.05 (black) and 0.52 (grey) quality-adjusted life years (QALYs) gained with ASA prophylaxis in pregnancy \[[@pone.0116296.ref001]\].\
CER~min~ calculated as: TER + \[DC / (QALYs gained x \$50 000)\], assuming a direct cost (DC) of ASA of \$10 per pregnancy. The dashed blue lines indicate that at a TER for preeclampsia of 6.0% and a QALY gain of 0.52 \[[@pone.0116296.ref001]\], the CER~min~ for preeclampsia is close to the TER (6.0%). At a smaller QALY gain of 0.05, a TER of 6.0% corresponds to a slightly higher CER~min~ of 6.4% (dashed red lines).](pone.0116296.g002){#pone.0116296.g002}

If we fix the TER at 6.0%---a rate observed in many ASA RCTs \[[@pone.0116296.ref011], [@pone.0116296.ref012], [@pone.0116296.ref014]\]---we see how the CER~min~ changes with varying QALYs gained ([Fig. 3](#pone.0116296.g003){ref-type="fig"}). The CER~min~ declines with increasing QALYs gained, but these changes become very minor above a QALY gain of 0.05.

![Minimum control event rate (CER~min~) for preeclampsia with varying quality-adjusted life years (QALYs) gained, at a fixed treatment event rate (TER) for preeclampsia of 6.0%.\
CER~min~ calculated as: TER + \[DC / (QALYs gained x \$50 000)\], assuming a direct cost (DC) of ASA of \$10 per pregnancy. The dashed blue lines indicate that at 0.52 QALYs gained \[[@pone.0116296.ref001]\], the CER~min~ for preeclampsia is close to the TER (6.0%). At a more modest gain of 0.05 QALYs, the CER~min~ increases slightly to 6.4% (dashed red lines).](pone.0116296.g003){#pone.0116296.g003}

We can also determine how the CER~min~ changes with DC. Under the reality that ASA is cheap, we see that the TER very closely approximates the CER~min~ for even a small QALY gain ([Fig. 4](#pone.0116296.g004){ref-type="fig"}). If ASA were much more expensive, then our threshold to treat would increase dramatically, and few women could achieve the required level of risk.

![Minimum control event rate (CER~min~) for preeclampsia with varying treatment event rates (TER) for preeclampsia at fixed values of 0.05 (black) and 0.52 (grey) quality-adjusted life years (QALYs) gained with ASA prophylaxis in pregnancy \[[@pone.0116296.ref001]\], and varied by two direct costs (DC) of ASA: \$10 (actual cost, triangles) and \$1 000 (circles).\
CER~min~ calculated as: **TER + \[DC / (QALYs gained x \$50 000)\]**. At a TER of 6.0% and a DC of ASA of \$10, the CER~min~ for preeclampsia is essentially the same as the TER with 0.05 or 0.52 QALYs gained (6.4% and 6.0%, respectively). At a TER of 6.0%, but a DC of ASA of \$1000, the CER~min~ increases to 9.8% with 0.52 QALYs gained (dashed blue lines) and 46.0% with 0.05 QALYS gained (dashed red lines).](pone.0116296.g004){#pone.0116296.g004}

Application of MERT to preeclampsia prophylaxis with ASA {#sec009}
--------------------------------------------------------

Sinclair et al. developed the *minimum event rate for treatment* (MERT) in order to arrive at the event rate (i.e., absolute risk) to justify starting a specific treatment for a given disease \[21\]. The equation for the MERT is as follows: $$MERT = 1/\left( {NNP_{T} \times RRR} \right)\lbrack 21\rbrack.$$

As expected, the MERT changes with varying NNP~T~ \[21\], and is highest when the NNP~T~ (and corresponding QALY gained) is lowest ([Fig. 5](#pone.0116296.g005){ref-type="fig"}). Not only does the MERT decline (i.e., improve) with increasing NNP~T~, but so too does the MERT decline with greater efficacy of ASA, indicated by a higher RRR against developing PE ([Fig. 5](#pone.0116296.g005){ref-type="fig"}).

![Minimum event rate for treatment (MERT) for ASA to prevent preeclampsia at varying thresholds of number needed to prevent (NNPT) and at 10%, 30% and 50% relative risk reductions (RRR) for the efficacy of ASA.\
NNP~T~ calculated as: (QALYs gained x \$50000) / DC \[[@pone.0116296.ref024]\], assuming a direct cost (DC) of ASA of \$10 per pregnancy. MERT is calculated as: 1 / (NNP~T~ x RRR) \[21\]. At a NNP~T~ of 250 (corresponding to 0.05 QALYs gained), the MERT is 1.3% (dashed red lines), which declines to 0.13% when the NNP~T~ is 2600 (corresponding to 0.52 QALYs gained, \[dashed blue lines\]).](pone.0116296.g005){#pone.0116296.g005}

Discussion {#sec010}
==========

When initiated in the window between 12 to 16 weeks gestation, ASA effectively reduces the risk of PE and its related adverse perinatal outcomes, including intrauterine growth restriction, preterm birth, and neonatal death \[[@pone.0116296.ref011]--[@pone.0116296.ref014], [@pone.0116296.ref027]\]. To date, there is no objective estimate about the threshold of risk to warrant ASA prophylaxis in a given woman. This uncertainty may partly contribute to the variability in recommendations for ASA prophylaxis, or its uptake among practitioners, resulting in ASA being unnecessarily withheld in some women \[[@pone.0116296.ref016]\].

To help address this problem, we proposed using the CER~min~, which, based on the TER and NNP~T~, arrives at the absolute risk (i.e., threshold rate) at which prophylaxis is indicated. The CER~min~ declines as a preventive therapy becomes more effective and less costly. The CER~min~ is conceptually similar to the MERT \[21\], but the former relies on knowing the TER and NNP~T~, and the latter on knowing the RRR and NNP~T~. Both the CER~min~ and the MERT are estimated with a degree of uncertainty \[[@pone.0116296.ref028]\]. An advantage of the MERT is that RRRs conveniently express the magnitude of treatment effect and are transportable across populations with various baseline risk \[[@pone.0116296.ref029]\]. However, RRRs conceal the underlying absolute risks, while TERs do not.

One concern about using the equation for NNP~T~ by Shimbo et al. \[[@pone.0116296.ref024]\] is that it does not account for the costs saved by avoiding PE-related events, thereby overestimating the CER~min~ and the MERT. Additionally, it does not account for potential adverse effects (i.e., harm) conferred by a treatment and the resultant associated costs, in terms of DC and QALYs lost. However, in the specific case of ASA prophylaxis for PE, the NNP~T~ formula by Shimbo et al. appears valid, as ASA has no demonstrable adverse effects on the pregnancy, delivery or the neonate \[[@pone.0116296.ref003], [@pone.0116296.ref015]\]. As an example, one RCT assigning 9364 pregnant women either ASA or matching placebo found that ASA was not associated with significant increases in placental haemorrhages or in bleeding during preparation for epidural anaesthesia \[[@pone.0116296.ref030]\]. In the EAGeR trial, which assigned women with prior spontaneous pregnancy loss to ASA 81 mg daily (615 women) or placebo (613 women), from preconception until 36 weeks' gestation or completion of 6 menstrual cycles, the risk of side effects and adverse events was the same in both groups \[[@pone.0116296.ref031]\]. However, in those ASA RCTs with smaller sample sizes, large beneficial effect sizes are more likely to be seen, while the chance of detecting rare adverse outcomes is reduced \[[@pone.0116296.ref032], [@pone.0116296.ref033]\].

The NNP~T~ values that we calculated for ASA prophylaxis were very high, and the subsequent CER~min~ and MERT values very low---a product of ASA's extremely low cost and absence of known adverse effects. The MERT, even at conservative estimates of QALYs gained, was mostly under 1%, which is seemingly too low to truly reflect the absolute risk of PE that can justify ASA prophylaxis. The estimates of the CER~min~, though not as dramatically low as those for the MERT, were often barely higher than the TER. At such low CER~min~ or MERT values, a clinician might be tempted to recommend ASA to a woman with no known risk factors---ASA can conceivably prevent PE with no associated risks and a minimal cost. However, the clinician and/or patient may decide to forgo ASA prophylaxis when her risk of PE is low, and there remains the potential to introduce a rare side effect from ASA, and/or there is a minor inconvenience of taking ASA. A future study should measure the preferences of a group of caregivers and parents, to see if the risk threshold for starting ASA differs from the CER~min~ or MERT.

Although the methods used herein may slightly underestimate the threshold risk for PE to warrant ASA prophylaxis, our results suggest that eligible women need not be at "high risk" for PE, but rather, at some modestly elevated risk. In the development of a clinical prediction rule that identifies women at risk of PE, the threshold adopted to consider ASA prophylaxis may only need to be slightly higher than that of the general population, perhaps somewhere between 6% and 10% \[[@pone.0116296.ref011]--[@pone.0116296.ref014]\]. Ideally, the threshold range we have provided can help physicians choose the right woman in whom ASA prophylaxis is warranted. Nonetheless, using this threshold as a guide would be enhanced by having more information on the contributions of common clinical risk factors for the development of PE, independently, and in combination; that is, we need a very simple and accurate tool for determining a woman's absolute risk of PE in the first trimester of pregnancy, before 12 to 16 weeks gestation. Finally, it is worthwhile to further investigate the efficacy and QALYs gained from ASA prophylaxis separately for the mother and her baby.
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